SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 200.79-0.2%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Machaon who wrote (23445)7/22/1998 9:51:00 PM
From: Henry Niman  Read Replies (3) of 32384
 
Bob, A physician can legally prescribe an FDA approved drug for any condition that the physician deems beneficial. This is unrelated to the FDA modernization act. Under the old rules, a company could not promote off label use (they could only promote for the on label application). Under the new rules, a company can promote off label uses. I believe that the requirement for promotion is publication in one or two peer reviewed articles.

Thus, as soon as ONTAK, Panretin, or Targretin is approved for a small indication, a physician can prescribe it for anything. As soon as off label uses are published, LGND can promote the off label use directly to the physician.

P.S. Today the Keystone State Stealers won 16-2, so I'm still in Columbus at the fast pitch World Series.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News